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Abstract The six-minute walking test (6MWT) may be a
practical test for the evaluation functional exercise capacity
in children with end-stage renal disease (ESRD). The aim
of this study was to investigate the 6MWT performance in
children with ESRD compared to reference values obtained
in healthy children and, secondly, to study the relationship
between 6MWT performance with anthropometric varia-
bles, clinical parameters, aerobic capacity and muscle
strength. Twenty patients (13 boys and seven girls; mean
age 14.1±3.4 years) on dialysis participated in this study.
Anthropometrics were taken in a standardized manner. The
6MWT was performed in a 20-m-long track in a straight
hallway. Aerobic fitness was measured using a cycle
ergometer test to determine peak oxygen uptake V

O2peak
 
,
peak rate (Wpeak) and ventilatory threshold (VT). Muscle
strength was measured using hand-held myometry. Chil-
dren with ESRD showed a reduced 6MWT performance
(83% of predicted, p<0.0001), irrespective of the reference
values used. The strongest predictors of 6MWT perfor-
mance were haematocrit and height. Regression models
explained 59% (haematocrit and height) to 60% (haema-
tocrit) of the variance in 6MWT performance. 6MWT
performance was not associated with V

O2peak, strength, or
other anthropometric variables, but it was significantly
associated with haematocrit and height. Children with
ESRD scored lower on the 6MWT than healthy children.
Based on these results, the 6MWT may be a useful
instrument for monitoring clinical status in children with
ESRD, however it cannot substitute for other fitness tests,
such as a progressive exercise test to measure V

O2peak or
muscle strength tests.
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Introduction
Children with end-stage renal disease (ESRD) are charac-
terized by multiple factors that influence their exercise
capacity, such as anaemia, metabolic acidosis, electrolyte
imbalance, osteopaenia, growth failure, undernutrition,
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fluid imbalance, muscle wasting and a sedentary life style
[1, 2].
In recent years exercise training has attracted interest as
a potential means to improve the stamina, endurance and
physical activity capacity of children and adults with ESRD
[3–5]. A practical test for the evaluation of the physical
activity capacity or functional exercise capacity of patients
with ESRD might be the six-minute walking test (6MWT)
[4, 6].
The 6MWT is a self-paced, submaximal exercise test
used to assess functional exercise capacity in children with
chronic diseases. It has been widely used in adults, most
extensively in patients with cardiopulmonary diseases, and
is currently the test of choice when a functional walk test
is required for clinical or research purposes [7]. The test is
well-standardized and easy to administer. The 6MWT is
increasingly being utilized in paediatric populations [8–10]
and has been found to be a valid estimate of physical fitness
in, for example, children with severe cardiopulmonary
disease, cystic fibrosis (CF) and juvenile idiopathic arthritis
(JIA) [11–13]. The test has shown good reliability [14, 15]
and is frequently employed to assess the response to
interventions [4, 16, 17]. However, there are some
limitations to this test; for example, it is unclear how hard
the patient is working and how its score is related to other
objective measures of exercise capacity in children with
chronic conditions like ESRD.
Reference values and prediction equations from healthy
children have recently been published, making it possible to
determine the predicted 6MWD for individual patients [18–
20]. Age, height, weight and gender are known to
independently predict 6MWD in healthy adults [21]. In
children, varying associations have been reported between
anthropometric variables, fitness variables and 6MWD [11,
13–15, 18, 19, 22].
The aim of the study reported here was to investigate
6MWT performance in children with ESRD compared to
reference values obtained in healthy children (discrimination
validity) and, secondly, to study the relationship between
6MWT performance with anthropometric variables, clinical
variables, aerobic fitness and muscle strength (construct
validity).
Patients and methods
Patients
Dutch speaking children between 8 and 18 years of age
with a diagnosis of ESRD and treated with either
haemodialysis or peritoneal dialysis for more than 3 months
were included. The patients had to be able to perform
exercise testing without musculoskeletal problems that
could limit the exercise testing, and they had to be able to
understand the exercise testing procedures. The eligible
patients were identified by a senior paediatric nephrologist
from each centre (JG, JN, KvH, ML).
A total of 25 children fulfilled the enrollment require-
ments and invited to participate. The parents of five
children refused to participate due to personal or logistic
reasons. Informed consent was obtained from all parents
and also from the children if they were older than 12 years
of age. The study was approved by the Medical Ethics
Committee of all participating centres.
Patients were recruited from the paediatric nephrology
outpatient clinic of the Wilhelmina Children’s Hospital
Utrecht, Emma Children’s Hospital Amsterdam, Sophia
Children’s Hospital Rotterdam and the University Hospital
Antwerp, Belgium. All children were tested in their local
hospital by the same research staff using the same mobile
equipment to reduce bias (MvB, TT and RHE).
Twenty patients were included in this cross-sectional
study. Eleven patients were treated with haemodialysis
(mean age 14.1±3.7 years), add nine were treated with
peritoneal dialysis (mean age 14.0±3.2 years). The medical
histories of these children were obtained from respective
hospital's patients’ medical records. A summary of their
medical history is presented in Table 1. To eliminate any
possible influence of a recent haemodialysis session on
exercise capacity, patients were tested immediately prior to
haemodialysis treatment or on an off-dialysis day.
Methods
Clinical characteristics
Standing height and weight were measured to the nearest
centimetre and 100 g, respectively, in a standardized
method, with the patient not wearing heavy clothing and
shoes. A body mass index (BMI) [weight (kg)/height (m2)]
was then calculated from these values. Subcutaneous fat
distribution was measured from skinfold measurements
using Harpenden skinfold callipers. The measurements
were taken at four sites, the triceps, biceps, subscapular
and supra-iliacal [23], and converted to percentage body fat
[24]. The systolic and diastolic blood pressure (mmHg) was
measured in a sitting position using an oscillometric blood
pressure device (Dinamap 8100 T; Critikon, Tampa, FL).
The values of height, weight, BMI and blood pressure were
compared with reference values for healthy, age- and
gender-matched children [25, 26].
Six-minute walk test
The 6MWT was performed on a 20-m track in a straight
hospital corridor. Patients were instructed to cover the
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largest possible distance in 6 min at a self-chosen walking
speed. Turns were made on both ends of the 20-m track.
The distance walked was recorded with a lap counter. At
1-min intervals, the patients were encouraged in a standard-
ized way [17] and time, recorded with a stopwatch, was
called. At the end of the test, the patient was asked to stand
still, and the distance covered in the final partial lap was
measured with measuring tape. The total distance covered
was calculated by multiplying the number of laps (back and
forth once) by 40 m and then adding the additional meters
of the final partial lap. The total distance walked was
rounded off to the nearest meter. The walking distance of
our subjects was compared with predicted 6MWD using the
gender-specific prediction equations from Geiger et al. [19]
and the height-specific centile charts from Li et al. [20].
Progressive exercise test
Patients performed a progressive exercise test using an
electronically braked cycle ergometer (Lode Corrival
Pediatric; Lode BV, Groningen, the Netherlands). The test
started with 1 min of unloaded cycling before the
application of resistance to the ergometer. After this first
minute, the work rate was increased with a constant
increment of 10, 15 or 20 W each minute based on height
according to the Godfrey protocol [27]. For patients
<120 cm, the work rate was increased by 10 W/min;
patients between 120 and 150 cm, by 15 W/min; patients
>150 cm, by 20 W/min. This protocol continued until the
patient voluntarily stopped because of exhaustion, despite
strong verbal encouragement of the test-leader. During the
test, subjects breathed through a facemask (Hans Rudolph,
Kansas City, MO) connected to a calibrated respiratory gas
analysis system (Cortex Metamax B3; Cortex Medical,
Leipzig, Germany). Expired gas was passed through a
flowmeter (Triple V volume transducer), an oxygen (O2)
analyser and a carbon dioxide (CO2) analyser. The
flowmeter and gas analysers were connected to a computer,
which calculated breath-by-breath minute ventilation V

E
 
,
oxygen uptake V

O2
 
, carbon dioxide output V

CO2
 
,
and the respiratory exchange ratio RER;¼ V CO2=V

O2
 
.
The oxygen uptake eliciting the ventilatory threshold (VT)
was determined by using the criteria of an increase in both
the ventilatory equivalent of oxygen V

E=V

O2
 
and end-
tidal pressure of oxygen (PETO2) with no increase in the
ventilatory equivalent of carbon dioxide V

E=V

CO2
 
[28]. Heart rate was measured continuously during the
maximal exercise test by using a heart rate monitor (Polar,
Kempele, Finland). Maximal effort was defined as meeting
one of the two criteria: heart rate >180 beats per minute or
RER >1.0. Peak work rate (Wpeak) was defined as the highest
work rate attained during the test.
Peak oxygen uptake V

O2peak
 
was defined as the
average value for the last 30 s during the maximal exercise
test. Relative V

O2peak was calculated as absolute V

O2peak
divided by body mass. Predicted V

O2peak and Wpeak values
were obtained from established reference values for age-
and gender matched healthy Dutch controls [29].
Characteristics Patients (n=20)
Time on dialysis (months) 27.5±38.2
Haemodialysis (%) 55
Causes of renal failure
Congenital structural abnormalities 4
Hereditary renal disorders 3
Glomerulonephritis 8
Systemic diseases 3
Other 1
Unknown 1
Hypertension medication
ACE inhibitors 4
ACE inhibitors + calcium blockers 1
ACE inhibitors + calcium blockers + beta-blockers 2
Calcium blockers 3
Calcium blockers + beta-blockers 2
None 8
Growth hormone 8
rHuEPO 20
Presence left ventricle hypertrophy 5
Table 1 Medical history of the
paediatric patients enrolled in
the study
ACE, Angiotensin converting
enzyme; rHuEPO, recombinant
human erythropoietin
Data are given as mean ± SD or
as n (%)
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Muscle Strength
Muscle strength was measured with a hand-held dynamo-
meter (Citec dynamometer CT 3001; C.I.T. Technics,
Groningen, the Netherlands) in Newton (N). Muscle groups
of the lower extremity assessed were knee flexors and
extensors, hip flexors, and dorsiflexors of the ankle joint.
Grip strength was also assessed as a indicator of global
muscle strength. Maximum muscle strength was tested with
the “break” method, in which the examiner gradually
overcomes the muscle force of the patient and stops at the
moment the extremity gives way.
Grip strength was measured using a Citec dynamometer
equipped with an extension for measuring grip strength
with the “make” method. Patients were sitting upright with
the arm in shoulder adduction and at 70° of flexion. The
elbow was flexed 30°. The extension was gripped as hard
as possible for 3 s without pressing the instrument against
the body and without touching the elbow to the body. Grip
strength was included as a indicator of global muscle
strength [30].
Every muscle group was measured three times, and the
highest score was recorded.
Reference values for muscle strength were obtained from
a study of healthy Dutch children [31].
Statistical analysis
Statistical analyses were performed with the use of the
Statistical Package for the Social Sciences for Windows
(ver. 13.0; SPSS, Chicago, IL). Prediction percentages were
calculated using the score of each individual patient divided
by the mean of the reference values for age and gender.
Differences in 6MWT performance between children with
ESRD and reference values was made using the Mann-
Whitney Rank Sum Test. Differences in anthropometric
variables, aerobic capacity, muscle strength and blood
pressure between children with ESRD and reference values
were made using independent samples t test.
The relationship between 6MWT performance and the
following independent variables height, weight, BMI,
haematocrit, hemoglobin, disease duration, muscle strength,
VT and V

O2peak was made using univariate Pearson
correlations and multiple backward linear regression
analysis.
Independent variables that showed a significant uni-
variate relationship (p<0.05) with the dependent variables
(% of predicted 6MWT performance according to the
reference values of Li et al. [20] or Geiger et al. [19]) were
entered in the final multiple linear regression model in
which variables with p>0.05 were excluded by means of
the backward procedure. The α-level was set at p<0.05
for all analyses.
Results
Twenty children (13 boys, seven girls; mean age ± SD 14.1±
3.4 years) were enrolled in the study. Anthropometrics and
clinical characteristics are illustrated in Table 2. Their mean
body fat percentage was 16.4±7.58% (range 5–31.1%).
Compared with the reference values, children with ESRD
had a significantly lower mean Z score for height and a
lower Z score.
In no case was it necessary to stop the tests prematurely,
and there were no unexpected events during the tests. The
6MWT performance of the patients is shown in Table 3 and
Fig. 1. Significantly reduced values were observed in the
children with ESRD compared to the references values of
Li et al. [20] (p<0.0001) and Geiger et al. [19] (p<0.0001).
Both set of reference values gave percentages of predicted
results and were highly correlated with each other (R=0.975,
p<0.0001). There was no significant difference in 6MWT
performance between the patients on haemodialysis and
those on peritoneal dialysis (p=0.7).
The mean HRpeak was 168.67±22.78 (range 131–201)
beats/min during the progressive exercise test, which was
significantly lower than the reference values (p<0.001).
Ten children did not meet the HR > 180 criterium. The
RERpeak was 1.15±0.15 (range 0.94–1.44), which was not
significantly different from that of healthy subjects. Two
children did not meet the RER > 1.0 criterium. One child
did not meet both HRpeak and RERpeak criteria. The
V

O2peak/kg of the patients was 30.9±7.0 (range 19.0-
43.0) ml/kg per minute, which is 66±12% of the predicted
value (p<0.0001). Seventeen patients had a V

O2peak/kg
lower than −2 SD. The Wpeak was 113.02±48.1 (range
42.5-220) W, which is 54.4±17% of the predicted (p<
0.0001). Only three patients had a Wpeak higher than −2
SD. The VT appeared at 32.7±8.9% (21.3–51.3%) of the
predicted V

O2peak, which is 55±15% of the predicted
compared to healthy subjects.
Muscle strength was, on average, 73±29 (p<0.001), 60±16
(p<0.0001), 62±15 (p<0.0001), 91±25 (p=0.49) and 62±
16% (p<0.0001) of that predicted for grip strength, knee
flexion, knee extension, foot dorsal flexion and hip flexion,
respectively. Of the total study population (n=20), 8, 11, 6, 2
and 8 patients had a muscle strength lower than −2 SD for
grip strength, knee flexion, knee extension, foot dorsal
flexion and hip flexion respectively.
Correlation analysis for height, weight, BMI, haematoc-
rit, hemoglobin, muscle strength and aerobic fitness showed
that only height, haematocrit, hemoglobin and VT were
significantly associated with 6MWD when considered as a
percentage of the reference values obtained by Li et al. [20]
and Geiger et al. [19]. Six-minute walking performance was
not associated with the use of antihypertensive medications,
growth hormone and recombinant erythropoietin.
2220 Pediatr Nephrol (2009) 24:2217–2223
Height, haematocrit and VT were entered in the backward
regression analysis (Table 4). Because haematocrit and
haemoglobin were strongly correlated (r=0.955, p<0.0001),
only haematocrit was entered in the regression analysis
because it had slightly higher correlation coefficients with
6MWT performance compared to haemoglobin (% predicted
according to Geiger et al.: r=0.707 vs. r=0.772; % predicted
according to Li et al.: r=0.651 vs. r=0.717, respectively).
Height and haematocrit were significant predictors of
6MWD performance using the Li et al. [20] reference
values, while haematocrit was the only significant predictor
of 6MWD performance using the Geiger et al. [19]
reference values. Both models predicted approximately
60% of the variance in 6MWT performance.
Discussion
The aim of the study reported here was to investigate the
6MWT performance of children with ESRD compared to
reference values obtained in healthy children (discrimina-
tion validity) and, secondly, to study the relationship
between 6MWT performance and anthropometric variables,
clinical variables, aerobic fitness and muscle strength
(construct validity).
We found that the 6MWT performance of the children
with ESRD participating in our study was significantly
lower than the reference values of Li et al. [20] and Geiger
et al. [19], but they were comparable to those reported
recently by Goldstein and Montgomery, who found a mean
6MWT distance of 538 m [4] in ten children receiving
haemodialysis. Compared to other children with a chronic
disease, our children with ESRD performed better that
those with JIA (approx.72 % of predicted) and ambulatory
children with spina bifida (approx. 60% of predicted), but
they performed worse than those with haemophilia (90% of
predicted) [9]. We are also able to confirm the previous
finding of Hassan et al. [9] that the reference values of
Li et al. [20] and Geiger et al. [19] are comparable when used
in children with a chronic disease. There are, however, slight
differences in the performance parameters of the 6MWT
between these two studies. For example, Geiger et al. [19]
used a measuring wheel as an incentive device during the
test and a 20-m track, while Li et al. used a 30.5-m track.
These differences do not seem to matter in terms of the
applicability of the reference values.
The strongest predictors for 6MWT performance in our
study were haematocrit and height. Height is not surprising
since it is known from work with healthy children that
height is a strong prediction of 6MWT performance.
Consequently, both reference values are based on height
Fig. 1 The six-minute walking performance of children with end
stage renal disease ESRD and healthy children (reference values
according to Li et al. [20]) in relation to height. HD haemodialysis,
PD peritoneal dialysis
Variables Mean ± SD (range) Z scores ± SD
Height (m) 1.48±0.20 (1.10-1.85) -2.0±1.4
Weight (kg) 44.6±18.1 (19.5-81.0) -0.83±1.5
Body mass index (kg/m2) 19.4±4.2 (15.0-31.0) 0.58±2.0
Σ 4SF (mm) 36.2±17.9 (15.0-71.6) 0.40±2.0
Hemoglobin (mmol/l) 7.4±1.0 (5.3-8.4) -
Haematocrit (l/l) 0.35±0.04 (0.25-0.42) -
Systolic blood pressure (mmHg) 122.2±18 (93-149) 1.4±1.7
Diastolic blood pressure (mmHg) 76.1±10.2 (63-101) 1.2±0.9
Table 2 Clinical characteristics
of the study cohort
Σ 4SF: sum of the four skin
folds
Table 3 Results of the six-minute walking test in children with end
stage renal disease
6MWT Mean ± SD Range
6MWT—Distance (m) 554.6±90.4 420-739
Predicted 6MWD—Li (m) 666.85±30.9 610-725
Predicted 6MWD—Geiger (m) 663.26±37.75 595–726
% predicted—Li 83.4%±11.04 68–109
% predicted—Geiger 83.3%±10.8 69-108
6MWD, 6-Minute walking test—distance; % predicted—Li, 6MWD
as a percentage of the reference values obtained from Li et al. [20]; %
predicted—Geiger, 6MWD as a percentage of the reference values
obtained from Geiger et al. [19]
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(Li et al. [20]) or age and height (Geiger et al. [19]). In an
earlier study in children with JIA, we also found that height
was a significant predictor of 6-min walking distance [22].
A greater height will result in a larger leg length and hence
a larger step length and walking speed.
Haematocrit was a strong predictor of 6MWT perfor-
mance as well. This was surprising as haematocrit was not
related to V

O2peak Wmax or muscle strength in our patients.
However, a previous study in anaemic adult patients who
were receiving haemodialysis, found that 6MWT distance
increased with increasing haemoglobin concentration
(correlation not reported) [32]. Moreover, increased exer-
cise capacity V

O2peak
 
has been reported in adult and
paediatric dialysis patients during their treatment of
anaemia using erythropoietin [33, 34], although the
V

O2peak response to increasing haematocrit in dialysis
patients was clearly blunted compared to healthy subjects
[35]. Based on this strong association with haematocrit, the
6MWT may be an interesting clinical outcome instrument
in children with ESRD.
Surprisingly, 6MWT performance was not significantly
related to lower extremity muscle strength, grip strength,
V

O2peak, Wpeak or VT. Previous studies in children with CF
[12] and cardiorespiratory disease [11] reported significant
associations between 6MWT performance and V

O2peak/kg
or Wpeak. A study in children with JIA, however, reported no
significant associations between 6MWT performance and
V

O2peak/kg or Wpeak [13]. None of these studies reported on
the relationship of BMWT performance and VT.
The children with ESRD in our study had a V

O2peak/kg of
31.3±7.0 (range 19–43) ml/kg per minute. Our patients
performed worse than those with CF, as reported in the study
of Gulmans et al. [12] (V

O2peak/kg 40.1±9.1, range 27–
60 ml/kg per minute), but better than the children with
cardiopulmonary conditions in the study of Nixon et al. [11]
(V

O2peak/kg 19.0±5.1, range 9.5–26.6 ml/kg per minute).
This difference is not surprising as the patients in the latter
study were candidates for lung and/or heart transplantations.
It is difficult to explain why the 6MWT performance
was unrelated to V

O2peak. Children with ESRD may have a
different sensation of their perceived exertion during
exercise because of abnormalities in their muscle metabo-
lism [2]. As such, they may select a walking intensity based
on oxygen delivery and/or a sensation of fatigue, which is
unrelated to V

O2peak but which may be restricted by
limitations in the skeletal muscle to extract oxygen [35].
Based on the significantly reduced values for aerobic
fitness and muscle strength that we found in our study, a
training programme may be indicated for children with
ESRD. However, two recent pilot-studies have encountered
significant challenges in patient adherence during such
exercise training programmes [3, 4]. Based on the findings
of Goldstein and Montgomery, the 6MWT seems to be a
sensitive instrument for recording performance improve-
ment as a result of exercise training in children with ESRD
[4]. Moreover, based on it’s strong association with
haematocrit, it may be an interesting clinical outcome
measure for monitoring the clinical status (e.g. anaemia) of
children with ESRD. However, more research is needed in
this area.
Future studies using the 6MWT in children with ESRD
should also determine the physiological strain of this test
(i.e. heart rate, oxygen uptake etc) as well as the
reproducibility of the test.
One limitation of this study is a possible selection bias.
Patients who participate in exercise studies may be more
interested in physical activity and may have a relatively
higher exercise capacity than those who do not. It is known
from the literature that self-selected subjects for an exercise
test have a 5–10% higher fitness level than a randomly
selected population [36]. In fact, the result may be
somewhat worse in an average population of children with
ESRD. Waever et al. [37] observed a V

O2peak/kg of
approximately 25 ml/kg per minute in 12 children with
ESRD on haemodialysis, and Painter et al. [2] reported a
mean V

O2peak/kg of 27.9 ml/kg per minute in 15 children
who underwent haemodialysis or peritoneal dialysis. Our
patients scored, on average, a somewhat higher V

O2peak/kg
(31.3 ml/kg per minute). This difference may be caused by
a higher body mass in the patients of the other studies [2,
37], as increased body mass is probably due to a higher
body fat percentage. Painter et al. [2] reported a mean body
fat percentage of 26.9%, which is quite a lot higher that the
percentage body fat in our subjects (16.4%).
In conclusion, we found that children with ESRD
performed significantly poorer on the 6MWT in comparison
with reference values and that their performance was
significantly associated with haematocrit and height. The
two sets of reference values used here provided similar results.
The 6MWT may be a useful instrument for monitoring
clinical status in children with ESRD, however it cannot
Table 4 Regression models of 6MWD as a percentage of the
reference values according to Li et al. [20] and Geiger et al. [19]
Variable Li et al. [20] Geiger et al. [19]
B
coefficient
95%
CI
B
coefficient
95%
CI
Constant 0.056 -0.283-
0.395
0.177 -0.93-
0.447
Haematocrit
(%)
-0.06 0.611-
2.376
1.886 1.116-
2.655
Height (m) 0.17 -0.022-
0.363
R2 0.59 0.60
B, Regression coefficient; CI, confidence interval
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substitute for other fitness tests, such as a progressive exercise
test to measure V

O2peak or a muscle strength test.
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